Saturday, 03 June 2023 11:37 GMT

Generic Oncology Drugs Global Market To Reach $36.9 Billion By 2027'

(MENAFN- PR Newswire)

DUBLIN, Nov. 24, 2022 /PRNewswire/ -- The 'generic oncology drugs market: global industry trends, share, size, growth, opportunity and forecast 2022-2027' report has been added to's

The global generic oncology drugs market size reached US$ 26.1 Billion in 2021. Looking forward, the publisher expects the market to reach US$ 36.9 Billion by 2027, exhibiting a CAGR of 5.94% during 2021-2027.Generic oncology drugs assist in shrinking, controlling and destroying the cancer cells present in the human body. Furthermore, a few oncology drugs are widely prescribed by doctors to alleviate symptoms, including pain. They share the same active ingredients as the already marketed brand-name cancer care medicine.

These drugs can be characterized by a different color or flavor than that of the original drug but their quality, performance, intended use, strength, dosage form and route of administration remain the same. Consequently, these drugs efficiently deliver equivalent clinical benefits and yield the same therapeutic effect as their brand-name counterparts at a lower cost.The escalating prevalence of cancer is one of the key factors driving the market growth. Owing to various factors including a rapid increase in the number of smokers, sedentary lifestyle and excessive exposure to ultraviolet (UV) rays, the number of cancer cases has experienced a significant rise across the globe.

In addition to this, the high costs associated with a full-length cancer treatment have led a majority of the patients to opt for these drugs as they are much more cost-effective as compared to their brand-name counterparts. Moreover, patent expiration of key blockbuster drugs is also a significant factor that is providing a boost to the market growth.

Along with this, governments of several countries are undertaking initiatives to promote generic drugs. They are continually engaging in research and development (R&D) activities to reduce healthcare expenses related to cancer treatment, thus making the healthcare facility accessible and affordable for all. Such initiatives are augmenting the introduction of several new generic drugs. Other factors such as rising awareness about the benefits of early cancer diagnosis and growing inclination toward preventive measures are contributing to the market growth. Key Market Segmentation: The publisher provides an analysis of the key trends in each sub-segment of the global generic oncology drugs market report, along with forecasts at the global and regional level from 2022-2027. Regional Insights:

  • North America
  • Europe
  • Asia Pacific
  • Middle East and Africa
  • Latin America

Amongst these, North America holds the leading position in the market, owing to an increasing number of cancer patients and rising awareness about early cancer diagnosis. Key Topics Covered: 1 Preface 2 Scope and Methodology 3 Executive Summary 4 Introduction 5 Global Generic Drug Market 6 Global Generic Oncology Drug Market 7 Global Generic Oncology Drug Market: Performance of Key Regions 8 Global Generic Oncology Drug Market: Competitive Landscape 9 Generic Oncology Drug Manufacturing Process 10 Project Details, Requirements and Costs Involved 11 Loans and Financial Assistance 12 Project Economics For more information about this report visit

Media Contact:

Research and MarketsLaura Wood, Senior Manager[email protected]
For E.S.T Office Hours Call +1-917-300-0470For U.S./CAN Toll Free Call +1-800-526-8630For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907Fax (outside U.S.): +353-1-481-1716


SOURCE Research and Markets


Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.